4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine | 617716-83-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine
• 英文别名: 4-chloro-2-cyclopropyl-5H,6H,7H,8H,9H-pyrimido[4,5-b]azepine
• CAS: 617716-83-3
• 化学式: C₁₁H₁₄ClN₃
• 分子量: 223.705
• InChiKey: QUIIKCJDJJQRFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  硫代吗啉 、 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine 生成 2-Cyclopropyl-4-thiomorpholin-4-yl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine
  参考文献：
  名称：

  First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives

  摘要：

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.006
• 作为产物：
  描述：

  [4-(2-cyclopropyl-4,6-dihydroxy-pyrimidin-5-yl)-butyl]-carbamic acid tert-butyl ester 在 丙二醇甲醚 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 生成 4-chloro-2-cyclopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]azepine
  参考文献：
  名称：

  First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives

  摘要：

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.006

文献信息

• [EN] CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSES CHIMIQUES A DOUBLE ACTIVITE, PROCEDES DE LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES
  申请人：UCB SA

  公开号：WO2003087064A1

  公开（公告）日：2003-10-23

  The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

  这项发明涉及化学化合物，它们既具有对人类m3肌肉收缩素受体的亲和力和拮抗作用，又具有作为选择性磷酸二酯酶IV（PDE IV）抑制剂的活性，以及制备它们的方法、含有它们的药物组合物以及它们作为药物的用途。
• Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
  申请人：Provins Laurent

  公开号：US20060074068A1

  公开（公告）日：2006-04-06

  The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

  本发明涉及一种化学化合物，它们具有亲和力和拮抗作用，针对人类m3肌动蛋白受体，并具有选择性磷酸二酯酶IV（PDE IV）抑制剂的活性，制备它们的过程，包含它们的制药组合物以及它们作为药物的用途。
• CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
  申请人：UCB, S.A.

  公开号：EP1499598A1

  公开（公告）日：2005-01-26
• US7544675B2
  申请人：——

  公开号：US7544675B2

  公开（公告）日：2009-06-09
• First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives
  作者：Laurent Provins、Bernard Christophe、Pierre Danhaive、Jacques Dulieu、Véronique Durieu、Michel Gillard、Florence Lebon、Sébastien Lengelé、Luc Quéré、BerendJan van Keulen

  DOI：10.1016/j.bmcl.2006.01.006

  日期：2006.4

  SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.